Hims & Hers Health (NYSE:HIMS) Beats Q4 Sales Targets But Stock Drops 16%
Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q4 CY2024, with sales up 95.1% year on year to $481.1 million. On top of that, next quarter’s revenue guidance ($530 million at the midpoint) was surprisingly good and 4.6% above what analysts were expecting. Its GAAP profit of $0.11 per share was in line with analysts’ consensus estimates.